The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncopeptides will raise proceeds of approximately SEK 1,106 million, before issue costs.
The share issue is directed to a number of selected international and Swedish reputable investors and life sciences specialist investors, on the basis of an accelerated bookbuilding process conducted by Carnegie, Cowen, DNB Markets, JP Morgan and Kempen & Co.
Oncopeptides is a clinical development pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company’s shares are admitted to trading on Nasdaq Stockholm.
Vinge’s team has consisted of Dain Hård Nevonen, Linnéa Sellström and Hampus Olsson.
